Peptide Storage: Best Practices for Research Integrity
A practical reference covering lyophilized storage conditions, reconstitution protocols, freeze-thaw management, and common degradation pitfalls.
Improper peptide storage is one of the most common and least-discussed sources of experimental variability in peptide research. A compound that performs inconsistently across experiments may not have a complex pharmacological explanation — it may simply be degraded material. This guide provides evidence-based protocols for maintaining peptide integrity from receipt through experimental use.
Lyophilized Peptide Storage
Lyophilized (freeze-dried) peptides are the most stable form for long-term storage. General guidelines:
- -20°C is appropriate for most peptides for up to 12 months. For highly sensitive or cysteine/methionine-containing sequences, -80°C is recommended.
- Peptides should be stored in desiccated, sealed vials. Do not open cold vials immediately upon removal from the freezer — allow vials to equilibrate to room temperature for 15–20 minutes before opening to prevent condensation from atmospheric humidity.
- Avoid repeated temperature cycling. Assign a dedicated storage aliquot separate from your working stock.
- Peptides with disulfide bonds are particularly vulnerable to oxidation during storage. Storage under inert gas (argon headspace) significantly extends stability.
Reconstitution Protocols
The choice of reconstitution solvent is peptide-dependent and should be guided by the compound's physicochemical properties:
- Bacteriostatic water (0.9% benzyl alcohol in WFI): The default for most research peptides. Suitable for subcutaneous administration in animal models. The benzyl alcohol preservative allows multiple draws from the same vial without microbial contamination.
- Sterile water for injection (WFI): Used when benzyl alcohol sensitivity is a concern or when the peptide will be used for in vitro assays where preservatives would confound results.
- Dilute acetic acid (0.1–1% v/v): Recommended for basic peptides (high proportion of Lys, Arg, His residues) that aggregate or precipitate in neutral aqueous solution.
- Dilute DMSO (<10%): For highly hydrophobic peptides that are insoluble in aqueous media. Always dilute to <0.1% final DMSO concentration before cell-based assays to avoid cytotoxicity.
Always reconstitute peptides gently — roll or invert the vial rather than vortexing. Mechanical shear can disrupt secondary structure in longer peptide sequences and promote aggregation.
Managing Freeze-Thaw Cycles
Repeated freeze-thaw cycles are a primary cause of peptide degradation in solution. Best practice is to aliquot reconstituted stock solutions into single-use volumes immediately after reconstitution. Label each aliquot with peptide ID, concentration, reconstitution date, and solvent. Discard unused thawed aliquots; do not re-freeze.
For experiments requiring precise dosing over extended periods, calculate total volume requirements upfront and create a complete aliquot set on the same day from the same stock solution. This eliminates batch-to-batch variability in your working solutions.
Quality Verification
For critical experiments, independent verification of peptide integrity adds substantial confidence to results. Reverse-phase HPLC with UV detection (214 nm for peptide bond absorption) can detect degradation products as deviations from the expected retention time profile. Mass spectrometry (ESI-MS or MALDI-TOF) confirms molecular weight and can identify oxidation (+16 Da on Met or Trp), deamidation (+1 Da on Asn or Gln), or disulfide scrambling. Certificate of Analysis (CoA) values reflect the material at time of manufacture; laboratories should consider periodic re-testing for long-term studies.
This article summarises published preclinical and, where noted, early clinical literature. It does not constitute medical advice and is not a claim that any compound is safe or effective for human use. Compounds referenced are supplied strictly for laboratory research.